Medexus Pharma is headquartered in Toronto, Ontario.
Medexus Pharma disclosed revenue of 108M USD for 2025 and 113M USD for 2024.
Medexus Pharma has 98 employees.
Medexus Pharma is a life science company.
10 King Street East, Suite 600,
Toronto, Ontario
M5C 1C3
Canada,
(877) 633-3987
www.medexus.com
Medexus Pharma is a pharmaceutical company dedicated to serving the needs of the pediatric community. The company's product portfolio includes NYDA, a breakthrough treatment for head lice; Relaxa, an osmotic laxative used to treat constipation; EpiCeram, a non-steroid emulsion for eczema; naproxen suspension, indicated to treat pain and inflammation due to various conditions, including Juvenile Idiopathic Arthritis; Rupall, an innovative new allergy medication with a unique mode of action; Otixal, the first and only antibiotic and steroid combination ear drop available in single, sterile, preservative-free and unit-dose packaging; and Cuvpos, for chronic severe drooling, a condition affecting a significant proportion of cerebral palsy patients. Medexus Pharmaceuticals is headquartered in Toronto, Canada.
| Year | ≤ '20 | '21 | '22 | '23 | '24 | '25 | T | |
|---|---|---|---|---|---|---|---|---|
| Buy (0.0/yr) | # | 3 | - | - | - | - | - | 3 |
| vol | $97M | $97M | ||||||
| Sell (0.0/yr) | # | - | - | - | - | - | - | 0 |
| 3 | ||||||||
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
